Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $7 | $7 | $8 |
| % Growth | 9.7% | 6.2% | -11.9% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $2 |
| Gross Profit | $6 | $6 | $5 | $6 |
| % Margin | 79.8% | 78.8% | 76.9% | 79.1% |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $4 |
| Operating Income | $3 | $2 | $2 | $2 |
| % Margin | 42.8% | 34.9% | 33.6% | 32.4% |
| Other Income/Exp. Net | $0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | $4 | $2 | $2 | $2 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | $3 | $2 | $1 | $2 |
| % Margin | 39.3% | 27.7% | 19.7% | 23.6% |
| EPS | 2.46 | 1.57 | 1.06 | 1.43 |
| % Growth | 56.7% | 48.1% | -25.9% | – |
| EPS Diluted | 2.43 | 1.56 | 1.04 | 1.42 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $5 | $3 | $3 | $3 |
| % Margin | 59% | 47.6% | 39.1% | 41.1% |